Skip to main content
Clinical Trials/NCT02221141
NCT02221141CompletedNot Applicable

Screening of Fabry Disease in Patients With Left Ventricular Hypertrophy Detected in Echocardiography

Laurence Gabriel1 site in 1 country120 target enrollmentStarted: December 2013Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Sponsor
Enrollment
120
Locations
1
Primary Endpoint
Percentage of patients with left ventricular hypertrophy who have Fabry Disease mutation

Study Overview

Brief Summary

The purpose of this study is to determine the prevalence in Belgium of Fabry disease in patients with unexplained hypertrophic cardiomyopathy measured by echocardiography and to determine in Fabry patients which was the most frequently initial symptom.

Actually the early diagnosis is important because a treatment exists that can prevent future complications.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Other

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • unexplained left ventricular hypertrophy

Exclusion Criteria

  • isolated septal hypertrophy

Outcomes

Primary Outcomes

Percentage of patients with left ventricular hypertrophy who have Fabry Disease mutation

Time Frame: 1 day

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
Laurence Gabriel
Sponsor Class
Other
Responsible Party
Sponsor Investigator
Principal Investigator

Laurence Gabriel

Dr Laurence GABRIEL

Centre Hospitalier Universitaire UCLouvain Namur

Study Sites (1)

Loading locations...

Similar Trials

Screening of Fabry Disease in Patients... | Clinical Trial